Teva Pharmaceutical Industries Limited (TEVA) Shares Sold by Loudon Investment Management LLC

Posted February 15, 2017

The company issued revenue guidance of $23.8-24.5 billion, compared to the consensus revenue estimate of $23.77 billion. Looking at the past 52 week period, the stock price is down -42.26%. Teva Pharmaceutical Industries Limited's payout ratio is now 67.44%. For the current quarter the stock has lowest EPS estimates of $1.17 and high estimate of $1.44. BTC Capital Management Inc. increased its position in shares of Teva Pharmaceutical Industries Limited by 13.4% in the second quarter. Hudock Capital Group LLC boosted its position in shares of Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Maxim Group restated a buy rating and issued a $52.00 target price (down from $72.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, November 16th. (TEVA) reported non-GAAP net income attributable to ordinary shareholders of $1.4 billion or $1.38 per share in the fourth quarter of 2016, compared to $1.1 billion or $1.28 per share in the fourth quarter of 2015. However the company's price to cash per share for most recent quarter stands at 20.64. Cash flow from operations fell 12 percent to $1.4 billion.Teva reaffirmed its 2017 forecast of EPS between $4.90 and $5.30, on revenue of between $23.8 billion and $24.5 billion.

"This is a critical time for Teva, and we are here to fix what is not working", he added during the company's call with investors Monday. Greatmark Investment Partners Inc. now owns 124,983 shares of the company's stock valued at $6,278,000 after buying an additional 352 shares in the last quarter. Teva Pharmaceutical Industries Limited has a 12-month low of $31.90 and a 12-month high of $59.35. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 14.1% in the third quarter. The Relative Volume value measured for Teva Pharmaceutical Industries Limited (NYSE:TEVA) is 2.18. The stock has a market capitalization of $34.42 billion, a P/E ratio of 19.73 and a beta of 0.58.

Among analysts who offered their Analysis on Teva Pharmaceutical Industries Limited (NYSE:TEVA)-6 analysts issued Strong buy for the stock, 8 analysts have given a Buy rating, 13 think it's a HOLD, 0 reported it as Underperform, while 0 analyst issued a Sell rating. Finally, Deutsche Bank AG lowered their price objective on shares of Teva Pharmaceutical Industries Limited from $68.00 to $54.00 and set a "buy" rating on the stock in a research report on Wednesday, November 16th.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is now showing its ROA (Return on Assets) of 2.4%. The company's 50-day moving average is $34.51 and its 200 day moving average is $42.93. The company's quarterly performance represents an optimistic momentum of 17.42 percent, with a surge of 11.03 percent in the stock price over the last one month. If you are reading this news story on another website, it was copied illegally and reposted in violation of global copyright and trademark laws. Buy rating has been given by 3 analysts to the company stock and 6 analysts given HOLD rating. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/02/14/teva-pharmaceutical-industries-limited-teva-price-target-lowered-to-33-00-at-jefferies-group-llc.html. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines.

Protesters block van from deporting Arizona mother
A Republic photo identified a woman looking through one of the vehicle windows covered by security screening as Garcia de Rayos. ICE officials said Rayos' removal under a voluntary deportation order was finalized by the Department of Justice in May 2013.

Revenue in its generic medicine segment grew 44% to $2.57 billion, largely due to the Allergan deal.

Yitzhak Peterburg took over as interim president and CEO of Teva, and the company has indicated that it is still searching for a permanent replacement for Vigodman.

Global sales of Copaxone rose 6 percent in the quarter to $1.0 billion.